HUE072392T2 - Bifunkcionális vegyületek a BTK bontására az ubikvitin proteoszóma útvonalon keresztül - Google Patents
Bifunkcionális vegyületek a BTK bontására az ubikvitin proteoszóma útvonalon keresztülInfo
- Publication number
- HUE072392T2 HUE072392T2 HUE20829249A HUE20829249A HUE072392T2 HU E072392 T2 HUE072392 T2 HU E072392T2 HU E20829249 A HUE20829249 A HU E20829249A HU E20829249 A HUE20829249 A HU E20829249A HU E072392 T2 HUE072392 T2 HU E072392T2
- Authority
- HU
- Hungary
- Prior art keywords
- bifunctional compounds
- proteosome pathway
- ubiquitin proteosome
- via ubiquitin
- degrading
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
- Luminescent Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943720P | 2019-12-04 | 2019-12-04 | |
| US202063010524P | 2020-04-15 | 2020-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE072392T2 true HUE072392T2 (hu) | 2025-11-28 |
Family
ID=74004152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE20829249A HUE072392T2 (hu) | 2019-12-04 | 2020-12-03 | Bifunkcionális vegyületek a BTK bontására az ubikvitin proteoszóma útvonalon keresztül |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11820781B2 (enExample) |
| EP (2) | EP4570320A3 (enExample) |
| JP (2) | JP2023504147A (enExample) |
| KR (1) | KR102998007B1 (enExample) |
| CN (1) | CN115003304A (enExample) |
| AU (2) | AU2020397920B2 (enExample) |
| BR (1) | BR112022010349A2 (enExample) |
| CA (1) | CA3160713A1 (enExample) |
| DK (1) | DK4069237T3 (enExample) |
| ES (1) | ES3033520T3 (enExample) |
| FI (1) | FI4069237T3 (enExample) |
| HU (1) | HUE072392T2 (enExample) |
| IL (1) | IL293797A (enExample) |
| MX (1) | MX2022006672A (enExample) |
| PL (1) | PL4069237T3 (enExample) |
| WO (1) | WO2021113557A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3867242A1 (en) | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| US12509455B2 (en) | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| WO2020097396A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020160295A1 (en) | 2019-01-30 | 2020-08-06 | Montelino Therapeutics, Llc | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| EP3924350A1 (en) | 2019-02-13 | 2021-12-22 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3932922A4 (en) | 2019-02-25 | 2022-05-11 | ShanghaiTech University | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
| KR102922115B1 (ko) | 2019-04-09 | 2026-02-04 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도 |
| CA3140873A1 (en) | 2019-05-17 | 2020-11-26 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| CA3294689A1 (en) | 2019-06-26 | 2026-03-02 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| US12653809B2 (en) | 2019-07-30 | 2026-06-16 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| CA3156828A1 (en) | 2019-10-03 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors and uses thereof |
| CA3160713A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| JP7815127B2 (ja) | 2020-02-19 | 2026-02-17 | ニューリックス セラピューティクス，インコーポレイテッド | インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用 |
| AU2021226514B2 (en) * | 2020-02-25 | 2023-10-19 | Shanghaitech University | Glutarimide skeleton-based compounds and application thereof |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
| MX2023012981A (es) * | 2021-05-03 | 2024-01-11 | Nurix Therapeutics Inc | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| KR20240026946A (ko) * | 2021-06-25 | 2024-02-29 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| KR20240029070A (ko) * | 2021-07-01 | 2024-03-05 | 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 | 브루톤 티로신 키나아제, 이의 돌연변이체 분해제, 조성물 및 응용 |
| IL309796A (en) | 2021-07-14 | 2024-02-01 | Nurix Therapeutics Inc | Bifunctional compounds for BTK degradation with reduced IMID activity |
| EP4373493A1 (en) | 2021-07-23 | 2024-05-29 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with enhanced imid activity |
| WO2023009709A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Pyrazolo piperazines as jak2 inhibitors |
| HUE070709T2 (hu) | 2021-08-18 | 2025-06-28 | Nurix Therapeutics Inc | Interleukin-1 receptorhoz kapcsolódó kinázok kétfunkciós lebontói és terápiás alkalmazásuk |
| CA3231240A1 (en) * | 2021-09-08 | 2023-03-16 | Sarat CHANDARLAPATY | Ink4 tumor suppressor proteins mediate resistance to cdk4/6 kinase inhibitors |
| US20240317734A1 (en) * | 2021-09-13 | 2024-09-26 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| WO2023059582A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| MX2024004899A (es) * | 2021-10-26 | 2024-05-24 | Nurix Therapeutics Inc | Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CN119823111B (zh) * | 2021-11-18 | 2026-05-05 | 正大天晴药业集团股份有限公司 | 稠合酰亚胺类衍生物 |
| CN118598858A (zh) | 2021-11-22 | 2024-09-06 | 杭州和正医药有限公司 | 一种可降解btk激酶的多功能化合物、组合物及应用 |
| AU2022405474B2 (en) * | 2021-12-08 | 2026-08-13 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications |
| KR20250020448A (ko) | 2022-06-02 | 2025-02-11 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | Bcl6을 억제하거나 분해하는 화합물 및 의약학에서의 응용 |
| WO2023239629A1 (en) | 2022-06-06 | 2023-12-14 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade cdk2 |
| CN117384161A (zh) * | 2022-07-04 | 2024-01-12 | 华东理工大学 | 靶向降解cdk蛋白的化合物及其应用 |
| KR20250037565A (ko) * | 2022-07-25 | 2025-03-17 | 셀진 코포레이션 | Irak3의 리간드 지정 분해제로서의 치환된 이미다조피라진 화합물 |
| EP4578849A4 (en) * | 2022-08-26 | 2025-11-26 | Fujifilm Corp | NEW PIPERAZINE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION |
| WO2024102970A1 (en) * | 2022-11-11 | 2024-05-16 | Kronos Bio, Inc. | Compounds for modulating syk activity and e3 ubiquitin ligase activity |
| EP4759807A1 (en) | 2023-08-11 | 2026-06-17 | Shenzhen Zhongge Biological Technology Co., Ltd. | Proteolysis targeting chimera compound for degrading irak4 and use thereof |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| CN122514523A (zh) * | 2023-10-23 | 2026-08-04 | 纽力克斯治疗公司 | 双官能化合物的盐和游离碱及其多晶型物形式 |
| WO2025162210A1 (zh) | 2024-02-04 | 2025-08-07 | 上海超阳药业有限公司 | 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途 |
| WO2025174220A1 (ko) * | 2024-02-14 | 2025-08-21 | 주식회사 유빅스테라퓨틱스 | Shp2 단백질 분해 활성을 갖는 화합물 및 이들의 의약 용도 |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004099388A2 (en) | 2003-03-05 | 2004-11-18 | Proteologics, Inc. | Cbl-b polypeptides, complexes and related methods |
| WO2007072225A2 (en) | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| WO2008033403A2 (en) | 2006-09-13 | 2008-03-20 | The Trustees Of Columbia University In The City Of New York | Agents and methods to elicit anti-tumor immune response |
| AT506041A1 (de) | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| ES2420846T3 (es) | 2008-02-05 | 2013-08-27 | F. Hoffmann-La Roche Ag | Nuevas piridinonas y piridazinonas |
| CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
| CA3034600C (en) | 2010-05-07 | 2020-11-10 | Genentech, Inc. | Pyridone and aza-pyridone compounds and methods of use |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| EP2471548A1 (de) | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| US20130110678A1 (en) | 2011-11-02 | 2013-05-02 | Apple Inc. | Purchasing a product in a store using a mobile device |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US8669251B2 (en) | 2011-11-03 | 2014-03-11 | Genentech, Inc. | 8-fluorophthalazin-1(2H)-one compounds |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US9499548B2 (en) | 2012-09-13 | 2016-11-22 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| AU2014360446A1 (en) * | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| BR112017025986A2 (pt) | 2015-06-02 | 2018-08-14 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton. |
| CN108026088B (zh) | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
| GB201614134D0 (en) * | 2016-08-18 | 2016-10-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN110099998A (zh) | 2016-10-26 | 2019-08-06 | 艾欧凡斯生物治疗公司 | 冷冻保存的肿瘤浸润淋巴细胞的再刺激 |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US10842878B2 (en) * | 2016-11-22 | 2020-11-24 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| CA3045037A1 (en) * | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| EP3743063A4 (en) | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND THEIR METHODS OF USE |
| JP2021512059A (ja) | 2018-01-29 | 2021-05-13 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法 |
| KR20210040355A (ko) | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
| EP3867242A1 (en) | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3924350A1 (en) | 2019-02-13 | 2021-12-22 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| KR102922115B1 (ko) | 2019-04-09 | 2026-02-04 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도 |
| CA3140873A1 (en) | 2019-05-17 | 2020-11-26 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| CA3294689A1 (en) | 2019-06-26 | 2026-03-02 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| US12653809B2 (en) | 2019-07-30 | 2026-06-16 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| WO2021091575A1 (en) | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| CN112812109B (zh) | 2019-11-18 | 2022-06-21 | 中国科学院微生物研究所 | 化合物DaP-01及其制备方法和应用 |
| CA3160713A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP4232023A4 (en) | 2020-10-26 | 2025-11-12 | Dana Farber Cancer Inst Inc | COMPOUNDS FOR THE TARGETED DEGRADATION OF KINASE PROTEINS |
| IL309796A (en) | 2021-07-14 | 2024-02-01 | Nurix Therapeutics Inc | Bifunctional compounds for BTK degradation with reduced IMID activity |
| EP4373493A1 (en) | 2021-07-23 | 2024-05-29 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with enhanced imid activity |
| MX2024004899A (es) | 2021-10-26 | 2024-05-24 | Nurix Therapeutics Inc | Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. |
| CN121548574A (zh) | 2023-04-28 | 2026-02-17 | 纽力克斯治疗公司 | 通过泛素蛋白酶体途径降解braf的双官能化合物 |
| CN122514523A (zh) | 2023-10-23 | 2026-08-04 | 纽力克斯治疗公司 | 双官能化合物的盐和游离碱及其多晶型物形式 |
-
2020
- 2020-12-03 CA CA3160713A patent/CA3160713A1/en active Pending
- 2020-12-03 AU AU2020397920A patent/AU2020397920B2/en active Active
- 2020-12-03 EP EP25161134.9A patent/EP4570320A3/en active Pending
- 2020-12-03 KR KR1020227022322A patent/KR102998007B1/ko active Active
- 2020-12-03 WO PCT/US2020/063176 patent/WO2021113557A1/en not_active Ceased
- 2020-12-03 HU HUE20829249A patent/HUE072392T2/hu unknown
- 2020-12-03 CN CN202080091041.XA patent/CN115003304A/zh active Pending
- 2020-12-03 EP EP20829249.0A patent/EP4069237B1/en active Active
- 2020-12-03 FI FIEP20829249.0T patent/FI4069237T3/fi active
- 2020-12-03 PL PL20829249.0T patent/PL4069237T3/pl unknown
- 2020-12-03 ES ES20829249T patent/ES3033520T3/es active Active
- 2020-12-03 BR BR112022010349A patent/BR112022010349A2/pt unknown
- 2020-12-03 IL IL293797A patent/IL293797A/en unknown
- 2020-12-03 DK DK20829249.0T patent/DK4069237T3/da active
- 2020-12-03 US US17/111,454 patent/US11820781B2/en active Active
- 2020-12-03 JP JP2022532148A patent/JP2023504147A/ja active Pending
- 2020-12-03 MX MX2022006672A patent/MX2022006672A/es unknown
-
2023
- 2023-03-10 US US18/120,341 patent/US12600732B2/en active Active
-
2025
- 2025-11-28 JP JP2025207457A patent/JP2026048713A/ja active Pending
-
2026
- 2026-02-27 US US19/552,781 patent/US20260193269A1/en active Pending
- 2026-07-21 AU AU2026207981A patent/AU2026207981A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260193269A1 (en) | 2026-07-09 |
| CN115003304A (zh) | 2022-09-02 |
| EP4570320A3 (en) | 2025-08-27 |
| US12600732B2 (en) | 2026-04-14 |
| AU2026207981A1 (en) | 2026-08-06 |
| FI4069237T3 (fi) | 2025-06-17 |
| IL293797A (en) | 2022-08-01 |
| US20230227471A1 (en) | 2023-07-20 |
| KR20220112273A (ko) | 2022-08-10 |
| AU2020397920B2 (en) | 2026-08-06 |
| EP4069237A1 (en) | 2022-10-12 |
| ES3033520T3 (en) | 2025-08-05 |
| US20210198280A1 (en) | 2021-07-01 |
| MX2022006672A (es) | 2022-08-08 |
| CA3160713A1 (en) | 2021-06-10 |
| US11820781B2 (en) | 2023-11-21 |
| EP4570320A2 (en) | 2025-06-18 |
| AU2020397920A1 (en) | 2022-06-16 |
| KR102998007B1 (ko) | 2026-07-31 |
| DK4069237T3 (da) | 2025-06-23 |
| WO2021113557A1 (en) | 2021-06-10 |
| JP2023504147A (ja) | 2023-02-01 |
| PL4069237T3 (pl) | 2025-08-04 |
| JP2026048713A (ja) | 2026-03-17 |
| EP4069237B1 (en) | 2025-04-09 |
| BR112022010349A2 (pt) | 2022-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4069237T3 (pl) | Związki dwufunkcyjne do degradacji btk za pośrednictwem szlaku ubikwityna–proteasom | |
| IL281904A (en) | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway | |
| GB201911928D0 (en) | Pharmaceutical compounds | |
| EP4276425C0 (en) | IMPROVED PLATFORM FOR PHARMACEUTICAL PRODUCT COMPOSTURE | |
| DK3648743T3 (da) | Pressede tabletter, der omfatter nitrooxyforbindelser | |
| GB201810245D0 (en) | Pharmaceutical compounds | |
| DK3486249T3 (da) | 99mtc-edda/hynic-ipsma som et radiofarmaceutisk middel til detektering af overekspressionen af prostata-specifikt membranantigen | |
| GB201810239D0 (en) | Pharmaceutical compounds | |
| EP3643639A4 (en) | COVER MATERIAL FOR PRESSURE PACKINGS | |
| SG11202009615UA (en) | Ox2r compounds | |
| EP3852792A4 (en) | INHIBITION OF UBIQUITIN-SPECIFIC PEPTIDASE 9X | |
| GB201819960D0 (en) | Pharmaceutical compounds | |
| GB201915273D0 (en) | Pharmaceutical compounds | |
| GB201914910D0 (en) | Pharmaceutical compounds | |
| GB201915932D0 (en) | Pharmaceutical compounds | |
| EP3452002A4 (en) | TWO-CHAMBRE PACKAGING FOR PHARMACEUTICAL COMPOSITIONS | |
| PL4003293T3 (pl) | Rozwój farmaceutyczny | |
| IL279698A (en) | Compounds that increase proteasome activity | |
| GB202103724D0 (en) | Pharmaceuticals solution for oral dosage | |
| GB201801562D0 (en) | Pharmaceutical compounds | |
| HUP2200205A1 (hu) | Termokatalitikus bontásra szolgáló készülék - szerves hulladékanyagok pirolízise | |
| IL291570A (en) | Pharmaceutical preparations | |
| EP3116989A4 (en) | A novel, high-throughput, nanotopographic platform for screening cell migratory behavior | |
| GB201800378D0 (en) | Pharmaceutical compounds | |
| PT4061328T (pt) | Comprimidos orodispersíveis de zonisamida |